Phase 3 Win for Azetukalner Makes XENE a Buy Despite a Premium
Xenon Pharmaceuticals' positive Phase 3 X-TOLE2 results for azetukalner (53.2% median seizure reduction vs 10.4% for placebo) and robust 48-month extension data justify a tactical long position. The company is well-capitalized after a $650M offering but trades at a premium - a buy for traders willing to accept biotech binary risk into an expected Q…